Erratum: Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes (Cell Reports (2016) 15(7) (1394–1400) (S2211124716304375) (10.1016/j.celrep.2016.04.024));Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes

Cell Reports

Volumn 15, Issue 7, 2016, Pages 1394-1400

  Konopka, Adam R ^a   Esponda, Raul Ruiz ^a   Robinson, Matthew M ^a   Johnson, Matthew L ^a   Carter, Rickey E ^a   Schiavon, Michele ^b   Cobelli, Claudio ^b   Wondisford, Fredric E ^c   Lanza, Ian R ^a   Nair, K Sreekumaran ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; LEUCINE; METFORMIN; PLACEBO;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIET RESTRICTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLUCAGONEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MORNING DOSAGE; OXIDATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL; TRANSAMINATION; BLOOD; DRUG EFFECTS; ENERGY METABOLISM; KINETICS; METABOLISM; REST;

ENERGY METABOLISM; FASTING; GLUCAGON; GLUCOSE; HUMANS; INSULIN; KINETICS; LEUCINE; METFORMIN; PREDIABETIC STATE; REST;

EID: 84964933150     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2018.05.027     Document Type: Erratum

References (36)

1. Diagnosis and classification of diatbetes mellitus. Diabetes Care 2014, 37:S81-S90. American Diabetes Association.
2. Buse J.B., DeFronzo R.A., Rosenstock J., Kim T., Burns C., Skare S., Baron A., Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care 2016, 39:198-205.
3. Cao J., Meng S., Chang E., Beckwith-Fickas K., Xiong L., Cole R.N., Radovick S., Wondisford F.E., He L. Low concentrations of metformin suppress glucose production in hepatocytes through AMP-activated protein kinase (AMPK). J. Biol. Chem. 2014, 289:20435-20446.
4. Charlton M.R., Nair K.S. Role of hyperglucagonemia in catabolism associated with type 1 diabetes: effects on leucine metabolism and the resting metabolic rate. Diabetes 1998, 47:1748-1756.
5. Charlton M.R., Adey D.B., Nair K.S. Evidence for a catabolic role of glucagon during an amino acid load. J. Clin. Invest. 1996, 98:90-99.
6. Cobelli C., Dalla Man C., Toffolo G., Basu R., Vella A., Rizza R. The oral minimal model method. Diabetes 2014, 63:1203-1213.
7. DeFronzo R.A., Barzilai N., Simonson D.C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. 1991, 73:1294-1301.
8. DeFronzo R.A., Hissa M.N., Garber A.J., Luiz Gross J., Yuyan Duan R., Ravichandran S., Chen R.S. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32:1649-1655. Saxagliptin 014 Study Group.
9. Duca F.A., Côté C.D., Rasmussen B.A., Zadeh-Tahmasebi M., Rutter G.A., Filippi B.M., Lam T.K. Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat. Med. 2015, 21:506-511.
10. Everett A.W., Prior G., Zak R. Equilibration of leucine between the plasma compartment and leucyl-tRNA in the heart, and turnover of cardiac myosin heavy chain. Biochem. J. 1981, 194:365-368.
11. Felig P., Wahren J., Hendler R. Influence of oral glucose ingestion on splanchnic glucose and gluconeogenic substrate metabolism in man. Diabetes 1975, 24:468-475.
12. Felig P., Wahren J., Sherwin R., Hendler R. Insulin, glucagon, and somatostatin in normal physiology and diabetes mellitus. Diabetes 1976, 25:1091-1099.
13. Foretz M., Hébrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., Andreelli F., Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
14. Galim E.B., Hruska K., Bier D.M., Matthews D.E., Haymond M.W. Branched-chain amino acid nitrogen transfer to alanine in vivo in dogs. Direct isotopic determination with [15N]leucine. J. Clin. Invest. 1980, 66:1295-1304.
15. Halvatsiotis P., Short K.R., Bigelow M., Nair K.S. Synthesis rate of muscle proteins, muscle functions, and amino acid kinetics in type 2 diabetes. Diabetes 2002, 51:2395-2404.
16. Haymond M.W., Miles J.M. Branched chain amino acids as a major source of alanine nitrogen in man. Diabetes 1982, 31:86-89.
17. He L., Wondisford F.E. Metformin action: concentrations matter. Cell Metab. 2015, 21:159-162.
18. He L., Sabet A., Djedjos S., Miller R., Sun X., Hussain M.A., Radovick S., Wondisford F.E. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009, 137:635-646.
19. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouli V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., Shulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49:2063-2069.
20. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 2002, 346:393-403. Diabetes Prevention Program Research Group.
21. Lalia A.Z., Johnson M.L., Jensen M.D., Hames K.C., Port J.D., Lanza I.R. Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans. Diabetes Care 2015, 38:1228-1237.
22. Lanza I.R., Zhang S., Ward L.E., Karakelides H., Raftery D., Nair K.S. Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS ONE 2010, 5:e10538.
23. Madiraju A.K., Erion D.M., Rahimi Y., Zhang X.M., Braddock D.T., Albright R.A., Prigaro B.J., Wood J.L., Bhanot S., MacDonald M.J., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510:542-546.
24. Miller R.A., Chu Q., Xie J., Foretz M., Viollet B., Birnbaum M.J. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013, 494:256-260.
25. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., Zhou G., Williamson J.M., Ljunqvist O., Efendic S., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002, 51:2074-2081.
26. Nair K.S., Halliday D., Garrow J.S. Increased energy expenditure in poorly controlled Type 1 (insulin-dependent) diabetic patients. Diabetologia 1984, 27:13-16.
27. Nair K.S., Halliday D., Matthews D.E., Welle S.L. Hyperglucagonemia during insulin deficiency accelerates protein catabolism. Am. J. Physiol. 1987, 253:E208-E213.
28. Nair K.S., Schwartz R.G., Welle S. Leucine as a regulator of whole body and skeletal muscle protein metabolism in humans. Am. J. Physiol. 1992, 263:E928-E934.
29. Nair K.S., Ford G.C., Ekberg K., Fernqvist-Forbes E., Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type I diabetic patients. J. Clin. Invest. 1995, 95:2926-2937.
30. Newgard C.B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012, 15:606-614.
31. Pain V.M., Albertse E.C., Garlick P.J. Protein metabolism in skeletal muscle, diaphragm, and heart of diabetic rats. Am. J. Physiol. 1983, 245:E604-E610.
32. Roden M., Perseghin G., Petersen K.F., Hwang J.H., Cline G.W., Gerow K., Rothman D.L., Shulman G.I. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J. Clin. Invest. 1996, 97:642-648.
33. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
34. Solis-Herrera C., Triplitt C., Garduno-Garcia Jde.J., Adams J., DeFronzo R.A., Cersosimo E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care 2013, 36:2756-2762.
35. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 1995, 333:550-554.
36. Zander M., Taskiran M., Toft-Nielsen M.B., Madsbad S., Holst J.J. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001, 24:720-725.